--- title: "Ari D Baron, M.D. | Sutter Health" url: "https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Investigators](https://www.sutterhealth.org/research/investigators) / 4. Ari D Baron, M.D. ![Ari D Baron, M.D.](https://dyn.mktgcdn.com/p/6yRtgxCIIRXiFOeBSBsWHHTovMS-k88mwc-hVtYQXNU/fit=crop,gravity=auto,dpr=2,width=240,height=240) # Ari D Baron, M.D. Investigator [View profile](https://www.sutterhealth.org/find-provider/dr-ari-d-baron-1046232245) Ari D. Baron, M.D., is Chief of the Division of Hematology Oncology at California Pacific Medical Center (CPMC), and Associate Clinical Professor of Medicine at UCSF. His practice has been at CPMC for over 20 years. Dr. Baron is the Medical Director of Clinical Oncology Research at CPMC, and the Chair of the Science Committee for Sutter Health Cancer Research Group. He also serves on the Board of Governor’s for South West Oncology Group (SWOG), one of the largest National Cancer Institute cooperative cancer research groups. Dr. Baron's main focus is in clinical research, where he has helped develop new medications for cancer patients across a broad array of diseases. He specializes in gastrointestinal cancers of the colon, liver, and pancreas, and urologic malignancies of the prostate and bladder. Dr. Baron was one of the clinical oncology leads at Sutter Health enrolling patients to the TAPUR™ study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs. He has co-authored numerous peer-reviewed publications in high-impact journals such as __The New England Journal of Medicine__ , __The Lancet__ , and the __Journal of the American Medical Association__ . These studies have helped secure FDA approval for treatments such as bevacizumab (Avastin®) a drug that inhibits blood vessels from supplying cancers and was approved for the treatment of colon cancer, and nivolumab (Opdivo®) an immunotherapy for bladder cancer. 2100 Webster Street Suite 225 San Francisco, CA 94115 ## Clinical trials - Clinical trial ### [Adjuvant Metastatic Urothelial Cancer CA244-0012 IZABRIGHT-Bladder01](https://www.sutterhealth.org/research/clinical-trials/adjuvant-metastatic-urothelial-cancer-ca244-0012-izabright-bladder01-2060655471) IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment **Status:** Closed to Enrollment - Clinical trial ### [Advanced Clear Cell Renal Cell Carcinoma S2419](https://www.sutterhealth.org/research/clinical-trials/advanced-clear-cell-renal-cell-carcinoma-s2419-2073485716) Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma \[BioFront Trial\] **Status:** Open to Enrollment - Clinical trial ### [Advanced Non-Small Cell Lung Cancer S1900K](https://www.sutterhealth.org/research/clinical-trials/interventional-lung-s1900k-lungmap-substudy-1049141939) A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) **Status:** Open to Enrollment - Clinical trial ### [Interventional Myeloma EQUATE EAA181](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964) Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation **Status:** Open to Enrollment - Clinical trial ### [Interventional Pancreatic APOLLO EA2192](https://www.sutterhealth.org/research/clinical-trials/interventional-pancreatic-apollo-ea2192-1049141957) APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation **Status:** Open to Enrollment Page 1 of 3 ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Investigators","item":"https://www.sutterhealth.org/research/investigators"},{"@type":"ListItem","position":4,"name":"Ari D Baron, M.D."}]} ``` ```json {"@context":"https://schema.org","@type":"ProfilePage","@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174#profilepage","url":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174","name":"Ari D Baron, M.D.","dateModified":"2026-06-03","breadcrumb":{"@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174#breadcrumblist"},"primaryImageOfPage":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/6yRtgxCIIRXiFOeBSBsWHHTovMS-k88mwc-hVtYQXNU/460x460.webp","width":460,"height":460},"mainEntity":{"@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174"}} ``` ```json {"@context":"https://schema.org","@type":"Person","@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174","name":"Ari D Baron, M.D.","givenName":"Ari","additionalName":"D","familyName":"Baron","honorificSuffix":"M.D.","description":"Ari D. Baron, M.D., is Chief of the Division of Hematology Oncology at California Pacific Medical Center (CPMC), and Associate Clinical Professor of Medicine at UCSF. His practice has been at CPMC for over 20 years. Dr. Baron is the Medical Director of Clinical Oncology Research at CPMC, and the Chair of the Science Committee for Sutter Health Cancer Research Group. He also serves on the Board of Governor’s for South West Oncology Group (SWOG), one of the largest National Cancer Institute cooperative cancer research groups. Dr. Baron's main focus is in clinical research, where he has helped develop new medications for cancer patients across a broad array of diseases. He specializes in gastrointestinal cancers of the colon, liver, and pancreas, and urologic malignancies of the prostate and bladder. Dr. Baron was one of the clinical oncology leads at Sutter Health enrolling patients to the TAPUR™ study, a national, prospective, non-randomized clinical trial determining the safety and efficacy of approved, targeted anticancer drugs. He has co-authored numerous peer-reviewed publications in high-impact journals such as The New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association. These studies have helped secure FDA approval for treatments such as bevacizumab (Avastin®) a drug that inhibits blood vessels from supplying cancers and was approved for the treatment of colon cancer, and nivolumab (Opdivo®) an immunotherapy for bladder cancer.","image":{"@type":"ImageObject","contentUrl":"https://a.mktgcdn.com/p/6yRtgxCIIRXiFOeBSBsWHHTovMS-k88mwc-hVtYQXNU/460x460.webp","representativeOfPage":true},"address":{"@type":"PostalAddress","streetAddress":"2100 Webster Street Suite 225","addressLocality":"San Francisco","addressRegion":"CA","postalCode":"94115","addressCountry":"US"},"affiliation":{"@id":"https://www.sutterhealth.org/#medicalorganization"},"mainEntityOfPage":{"@id":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174#profilepage"},"sameAs":"https://www.sutterhealth.org/find-provider/dr-ari-d-baron-1046232245"} ```